Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients

Amazon.com Inc.‘s (NASDAQ:AMZN) Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access.

Benzinga

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance.

Benzinga

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

The Guardian - UK

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Despite Trump's backing, Vivek Ramaswamy can't curry favor with MAGA bros in Ohio

The TOI correspondent from Washington : Every Indian child grows up hearing at least two pieces of parental advice: study hard, and don't talk back. Vivek Ramaswamy followed the first well enough to become a biotech billionaire before he turned forty. But talking down at a tetchy MAGA townhall on…

The Times of India

One in Three U.S. Communities Has No Preferred Medicare Pharmacy, and That Gap Changes What Seniors Pay

One in three U.S. ZIP code areas lacks a preferred Medicare pharmacy, a new study finds. Here is how that gap changes what seniors pay.

Medical Daily

Public Comment Closes on the FDA Plan to Permanently Bar Bulk Compounding of Semaglutide and Tirzepatide

The comment window on FDA's proposal to keep semaglutide and tirzepatide off the 503B bulk list closed July 30. No final decision has been announced.

Medical Daily

Active U.S. Drug Shortages Have Risen to 223, and Two Official Counts Disagree on the Scale

Pharmacists count 223 active US drug shortages while the FDA tracks far fewer. Here is why the two numbers differ and what it means for patients.

Medical Daily

Judge Says the FDA Never Explained Why Mifepristone Prescriber Certification Was Necessary

A federal judge ruled the FDA failed to justify its 2023 mifepristone REMS requirements. The rules stay in effect while the agency reconsiders.

Medical Daily

Medicare to End Premium Stabilization Program for Standalone Drug Plans

CMS is ending the Part D Premium Stabilization Demonstration after 2026. Here is what it did and what seniors will learn in September.

Medical Daily

Trump Administration Pulls the Plug on a Medicare Subsidy That Cut Drug Premiums— Oz Says the 'Bailout' Is Over as Seniors Brace for 2027 Hikes

The Centers for Medicare & Medicaid Services (CMS) announced Tuesday it will end the Medicare Part D Premium Stabilization Demonstration after the 2026 plan year, ending a federal subsidy program that has helped keep prescription drug premiums lower and could result in higher costs for some seniors beginning in 2027.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

GSK heads to Cambridge with long-awaited positive vibes

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

Medical Daily

If Your Weight Loss Injection Comes From a Compounder, Here Is What to Ask Before the Next Refill

Compounded GLP-1 users face a July 30 FDA comment deadline. Here is how to tell what you are taking and what to ask your pharmacy.

The Guardian - UK

GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development

Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site

Medical Daily

ADHD And Chronic Pain Patients May Struggle To Fill Prescriptions As Controlled Substance Shortages Persist Nationwide

ASHP says 16% of active drug shortages are controlled substances. Here is how partial fills and prescription transfers work at the pharmacy counter.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

International Business Times

Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns

Erez Israeli, CEO of Dr. Reddy's Laboratories, said that President Donald Trump's proposed tariffs on imported generic medicines would inevitably translate into higher prices for patients.

The Guardian - UK

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’

Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot

Medical Daily

DEA Could Ban Concentrated 7-OH Kratom Products Any Time After August 5 — What Consumers Need to Know

DEA's temporary Schedule I order for concentrated 7-OH kratom products can issue any time after August 5. What the threshold covers and who is affected.

Benzinga

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

President Donald Trump has given generic-drug manufacturers a choice – add U.S. capacity within two years or face tariffs.

International Business Times

Pfizer and the $200 Billion-Dollar Cardiovascular Market

Pfizer's cardiovascular business highlights the intersection of drug pricing, marketing, patents, and competition in the rapidly growing $200 billion heart disease market.

Bangkok Post

US panel says to loosen restrictions on popular peptide despite safety concerns

NEW YORK - A US review panel on Thursday recommended loosening restrictions on the much hyped peptide BPC-157, voting that specialized pharmacies be allowed to produce it despite alarm bells from medical experts over safety concerns.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.